No Stock Yet
02367 GIANT BIOGENE
50.500-2.500-4.72%
YOY
Do not show
(FY)2021/12/31(FY)2020/12/31(FY)2019/12/31
Turnover
30.41%
1.55B
24.44%
1.19B
--
956.7M
Operating income
30.41%
1.55B
24.44%
1.19B
956.7M
Cost of sales
-8.04%
-198.15M
-14.64%
-183.41M
--
-159.99M
Operating expenses
-8.04%
-198.15M
-14.64%
-183.41M
-159.99M
Gross profit
34.48%
1.35B
26.40%
1.01B
796.71M
Selling expenses
-118.54%
-346.21M
-68.91%
-158.42M
--
-93.79M
Administrative expenses
-119.07%
-72.27M
-14.38%
-32.99M
--
-28.85M
Research and development expenses
-86.49%
-24.95M
-17.38%
-13.38M
--
-11.4M
Impairment and provision
-113.15%
-326K
342.09%
2.48M
--
-1.02M
-Other impairment is provision
-113.15%
-326K
342.09%
2.48M
--
-1.02M
Special items of operating profit
-63.00%
62.35M
998.29%
168.49M
--
15.34M
Operating profit
-0.03%
972.92M
43.76%
973.24M
677M
Earning before tax
-0.03%
972.92M
43.76%
973.24M
677M
Tax
1.34%
-144.79M
-44.14%
-146.76M
--
-101.82M
After-tax profit from continuing operations
0.20%
828.13M
43.69%
826.49M
575.18M
Earning after tax
0.20%
828.13M
43.69%
826.49M
575.18M
Minority profit
--
--
-99.85%
35K
--
22.92M
Profit attributable to shareholders
0.20%
828.13M
49.65%
826.45M
552.26M
Basic earnings per share
0.00%
0.83
50.91%
0.83
0.55
Diluted earnings per share
0.00%
0.83
50.91%
0.83
0.55
Currency Unit
CNYCNYCNY
Accounting Standards
IASIASIAS
Audit Opinions
Unqualified OpinionUnqualified OpinionUnqualified Opinion
Auditor
Ernst & YoungErnst & YoungErnst & Young
Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.
The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%
Company Overview
More
Juzi Biotech Holdings Co., Ltd. is a Chinese investment holding company. Through its subsidiaries, the company is mainly engaged in the R&D, production and sale of beauty and health products based on bioactive materials. The company's main products include functional skincare products and medical dressings, and the key bioactive ingredient in its products is recombinant collagen. The company also develops and produces rare functional foods based on ginsenoside technology. The company mainly conducts its business in the domestic market.
CEO： Jianya Yan
Market： Hong Kong motherboard
Listing Date： 11/04/2022
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist